COPD – GSK 224295

Profound Research and Clarkston Medical Group are enrolling for a COPD study that is assessing an investigational medication against placebo when added to your standard-of-care (SoC) treatment to see if it reduces the frequency of moderate-to-severe flare-ups.

To be eligible to participate, you must:

• Be aged 40-75 with a BMI > 16
• Be diagnosed with moderate-to-severe COPD with type 2 inflammation
• Have documentation of only 1 moderate COPD flare up in the past 12 months; Must have been treated with systemic corticosteroids during this flare
• Have at least 1 risk factor for future flare-ups
• Be a current or former cigarette smoker with a history of at least 10-pack years (1 pack/day for at least 10 years)
• Be taking an optimized dual or triple inhaler therapy for at least 3 months
• Not have current or prior asthma (childhood asthma is allowed if resolved before age 18)

Additional criteria apply.

Qualified participants will receive:

• Study-related care and study medication at no cost
• Financial compensation for time and travel expenses